Current and Future Therapeutics for Treating Patients with Sickle Cell Disease

Area of Science:

• Hematology
• Medical Genetics
• Pharmacology

Background:

• Sickle cell disease (SCD) is a prevalent genetic blood disorder affecting over 100,000 individuals in the U.S.
• Abnormal hemoglobin variants cause red blood cell dysfunction in SCD patients.
• Recent advancements include FDA-approved gene therapies offering potentially curative options.

Purpose of the Study:

• To review ongoing clinical trials for sickle cell disease therapies with completion dates in 2024 or later.
• To explore the current landscape of SCD therapeutics, including novel and FDA-approved gene therapies.
• To highlight the need for research into long-term effects and cost-effective treatments for SCD.

Main Methods:

• Comprehensive review of clinical trials for sickle cell disease.
• Analysis of current and emerging therapeutic strategies.
• Focus on trials with completion dates in 2024 and beyond.

Main Results:

• Several novel gene therapies have been approved, offering new treatment avenues for SCD.
• Ongoing trials are investigating long-term pharmacological effects, particularly on the brain and kidneys.
• Research continues to focus on developing more affordable and effective SCD treatments.

Conclusions:

• FDA-approved gene therapies represent a significant advancement in SCD treatment, potentially offering cures.
• Further research is essential to address questions regarding long-term safety, efficacy, and accessibility of current and future therapies.
• Continued investigation into novel treatments aims to provide more effective and economical solutions for sickle cell disease patients.